Drug data last refreshed 9h ago · AI intelligence enriched 2d ago
AKINETON (biperiden lactate) is an anticholinergic agent administered via injection used to treat extrapyramidal side effects induced by antipsychotic medications. It works by blocking cholinergic neurotransmission in the central nervous system to counteract dopamine-blocking effects. This is an adjunctive therapy for managing acute dystonia, akathisia, and parkinsonism in psychiatric patients.
As an older injectable with LOE approaching, this product likely operates with a lean team focused on maintaining institutional and hospital relationships rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on AKINETON offers limited growth opportunity given its LOE status and minimal linked job postings; this is a maintenance-focused role suited for professionals prioritizing stability and operational expertise over high-visibility launches. Career advancement typically requires transition to growth-stage products within the AbbVie portfolio.
Worked on AKINETON at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.